{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:24Z","timestamp":1786987044915,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.clinthera.2016.12.005","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T20:46:59Z","timestamp":1482871619000},"page":"212-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Combination Therapy With Vancomycin and Ceftaroline for Refractory Methicillin-resistant Staphylococcus aureus Bacteremia: A Case Series"],"prefix":"10.1016","volume":"39","author":[{"given":"Diana","family":"Gritsenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fedorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg J.","family":"Ruhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Altshuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2016.12.005_bib1","first-page":"ii37","article-title":"Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?","volume":"51","author":"Nathwani","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib2","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2016.12.005_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2016.12.005_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0091270007312152","article-title":"Clinical microdialysis in skin and soft tissues: an update","volume":"48","author":"Schmidt","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2016.12.005_bib5","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0924-8579(00)00303-4","article-title":"Vancomycin treatment failures in staphylococcus aureus lower respiratory tract infections","volume":"16","author":"Moise","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2016.12.005_bib6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkf215","article-title":"The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin","volume":"50","author":"Moise","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1086\/346207","article-title":"Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001","volume":"36","author":"Fridkin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2016.12.005_bib8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2016.12.005_bib9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteremia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib10","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1128\/AAC.02354-12","article-title":"Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous VISA","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/107662903322762833","article-title":"In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium","volume":"9","author":"Jevitt","year":"2003","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.clinthera.2016.12.005_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10096-010-1128-3","article-title":"Emergency of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteremia in a daptomycin-na\u00efve patients\u2014a review of the literature","volume":"30","author":"van Hal","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2016.12.005_bib13","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/AAC.43.7.1747","article-title":"Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin","volume":"43","author":"Climo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.12.005_bib15","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1128\/AAC.00069-13","article-title":"Ceftaroline increases membrane binding and enhances activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamics model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2011.01.017","article-title":"Ceftaroline: a comprehensive update","volume":"37","author":"Kaushik","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2016.12.005_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.clinthera.2016.12.005_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1198-743X.2004.00856.x","article-title":"False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods","volume":"10","author":"Goldstein","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2016.12.005_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.05473-11","article-title":"In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus","volume":"56","author":"Hagihara","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/phar.1435","article-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","volume":"34","author":"Jain","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2016.12.005_bib22","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2146\/ajhp130474","article-title":"A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline","volume":"71","author":"Yam","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2016.12.005_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jcpt.12062","article-title":"Ceftaroline\u2014a cause for neutropenia","volume":"38","author":"Rimawi","year":"2013","journal-title":"J Clin Pharm Ther"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2016.12.005_bib24","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/cid\/cis559","article-title":"Summary of ceftaroline fosamil clinical trial studies and clinical safety","volume":"55","author":"File","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2016.12.005_bib25","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program","volume":"56","author":"Flamm","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib26","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/jac\/dku114","article-title":"Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective","volume":"69","author":"Alm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2016.12.005_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijantimicag.2014.12.014","article-title":"A multicentre study of methicillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology","volume":"45","author":"Zhang","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2016.12.005_bib28","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1128\/AAC.03622-14","article-title":"PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates","volume":"58","author":"Long","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816309183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816309183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T20:49:49Z","timestamp":1568666989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816309183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0149291816309183"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Therapy With Vancomycin and Ceftaroline for Refractory Methicillin-resistant Staphylococcus aureus Bacteremia: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}